Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Rheumatoid Arthritis
Status:
Terminated
Trial end date:
2017-11-14
Target enrollment:
Participant gender:
Summary
GSK3117391 has the potential to complement existing therapies in the treatment of chronic
inflammatory disorders such as rheumatoid arthritis (RA). This study will evaluate the
efficacy, safety and tolerability of oral GSK3117391 (Dose A) administered to subjects with
severe RA despite treatment with disease-modifying anti-rheumatic drugs (DMARDs). This is a
randomised, double-blind (sponsor open), multicentre, placebo-controlled, parallel group
study. The total maximum study duration is approximately 10 weeks. Following a screening
period of up to 28 days, subjects will be randomized (1:1) to placebo or GSK3117391 (Dose A)
administered orally for a period of 28 days. Subjects will be followed up for 7 to 14 days
post final dose. Approximately 40 subjects with severe RA will be randomised into the study.